WILSON ROBERT N

Director Robert N Wilson bought 4,500 CALC shares at $2.87; cluster activity amid +78.1% 30d rally from 52-week lows

Director Robert N Wilson purchased 4,500 shares of CalciMedica at $2.87, bringing his holdings to 422,029 shares. This buy occurs within a cluster—two other insiders also purchased within the past 14 days—while the stock has rallied 78.1% over 30 days and 94.2% over 90 days from depressed levels, currently trading 43.2% below its 52-week high of $5.30. Within his same-ticker history at CALC, Wilson achieved positive 90-day returns on 3 of 5 prior purchases (buy on 2024-06-28, 2024-06-27, and 2023-12-11), suggesting selective timing accuracy at this company. However, the company remains unprofitable with net income of $-5,042,000 for the most recent full fiscal year, a material fundamental headwind that constrains the bullish signal from recent price momentum and coordinated insider purchasing.

Director Wilson buys 53,333 shares at $3.75; stock down 52.8% from high, now -17.8% in 30d.

Director Robert N Wilson purchased 53,333 shares at $3.75 on 2024-11-01, increasing his holdings from 364.2K to 417.5K shares (+14.6%), while the stock trades at $3.51 (down 52.8% from its 52-week high of $7.44 and down 17.8% over the past 30 days). His prior 4 buys at CalciMedica have shown a 100% hit rate at the 90-day mark, with returns of +34.2%, +28.4%, +34.2%, and +36.4%, suggesting accurate timing in similar market conditions. However, CalciMedica remains unprofitable with net income of $-4.0M against a $37.7M market cap, and the current 30- and 90-day declines indicate sustained downward momentum since his purchase. A cluster pattern shows 4 other insiders also bought within 14 days, and Wilson's historical acumen at this ticker contrasts sharply with the stock's recent deterioration, warranting close observation of whether his positioning will again prove prescient or whether the current weakness reflects broader fundamental headwinds.

Director WILSON ROBERT N bought 54,000 shares of CALC at $3.72 (total $200.8K), raising holdings 17.4% to 364.2K shares amid unprofitable operations.

WILSON ROBERT N purchased 54,000 shares at $3.72 on 2024-08-23, a substantial 17.4% increase to his holdings of 364.2K shares—representing a director-level accumulation in a $44.4M market-cap biotech company reporting a net loss of $4.0M. His cross-ticker track record shows a 100% 90-day win rate with an average 90-day return of +36.4%, though this consists of only 3 prior buys across other tickers; at CalciMedica specifically, his 2023-12-11 buy achieved +36.4% over 90 days (the measurable outcome), while his two more recent June 2024 purchases are still in their observation window. The stock currently trades at $4.13, down -44.5% from its 52-week high of $7.44, suggesting the director is buying into a significantly depressed price environment. The company's ongoing unprofitability and the magnitude of this insider accumulation warrant close monitoring of the company's path to profitability and how the stock responds to future operational milestones.

Director Robert N Wilson bought 51,278 shares of CALC at $3.52 on 2024-06-28, second purchase in two days as stock down 46.1% from 52-week high.

Robert N Wilson, a director, executed a purchase of 51,278 shares at $3.52 on 2024-06-28, adding 19.8% to his holdings to reach 310,196 shares total. This buy occurred one day after another CALC purchase on 2024-06-27, suggesting sustained acquisition activity despite significant recent price weakness—the stock is down 46.1% from its 52-week high of $7.44 and has declined 29.4% over the prior 30 days. Across his open-market history at other tickers, Wilson's prior buys yielded a 100% 90-day win rate with an average 90-day return of 36.4%, and his most recent CALC buy on 2023-12-11 delivered a 36.4% 90-day return. However, the company remains unprofitable on a full-year basis despite reporting a quarterly net income of $130,000, introducing a structural uncertainty that overlaps this accumulation pattern. The repeated buying into a sharply depressed valuation warrants investor attention to both the director's conviction and the company's path to sustainable profitability.

Director Wilson bought 8,443 CALC shares at $3.23 on 2024-06-27; stock now $4.25, down 42.9% from 52-week high.

Director Robert Wilson purchased 8,443 shares of CalciMedica at $3.23, increasing his holdings by 3.4% to 258.9K shares. The current price of $4.25 reflects significant near-term volatility: the stock is down 25.2% over 30 days and down 42.9% from its 52-week high of $7.44, though it has recovered 5.2% over 90 days. Wilson's prior purchase at this ticker on 2023-12-11 saw a 36.4% gain over 90 days, establishing a pattern of accumulation when the stock weakens. The company's fundamentals remain challenging—CalciMedica reported negative net income over its most recent full fiscal year, making this transaction noteworthy as continued insider accumulation during a period of financial strain and stock price pressure. This pattern warrants monitoring to see whether the insider's historical timing edge holds in the current environment.